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ABSTRACT. Rhabdomyosarcoma (RMS) is a highly malignant cancer. 
Over the last two decades, prognosis for RMS patients has significantly 
improved, with the exception of those in the high-risk group. In order to 
identify new prognostic factors, we investigated the expression of nestin in 
RMS cells and its correlation with clinicopathological features and patient 
outcome. The analysis of overall survival for all patients (N = 30) revealed 
1-, 2-, 3-, 4-, and 5-year survival rates of 93.3, 83.3, 66.7, 63.3, and 63.3%, 
respectively. Nestin overexpression significantly correlated with survival (P 
= 0.044). Survival of patients with ≤50% nestin-positive cells was 90, 70, 
and 40% after 1, 2, and 3 years, respectively, and remained unchanged 
until the end of the investigation period. The study group composed of 
patients exhibiting nestin expression in >50% of cells showed 1-, 2-, 3-, 
and 4-year survival rates of 95, 90, 80, and 75%, respectively, remaining 
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stable at 75% for the fifth year of observation. A nestin-positive expression 
rate lower than 50% was observed more frequently in older patients (43.60 
± 27.58 years; P = 0.028). In addition, higher rates of nestin expression 
were observed in most embryonal RMS specimens and low-grade tumors, 
in early stages of the disease, and among younger patients. Our results 
lead us to propose nestin as possible positive prognostic factor in RMS.
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INTRODUCTION
Rhabdomyosarcoma (RMS) is malignant tumor comprised of neoplastic cells with 
evidence of skeletal muscle differentiation. RMS is the most common soft tissue sarcoma in 
childhood, accounting for 5-10% of all pediatric malignancies (Dasgupta and Rodeberg, 2012). 
Based on histological and molecular features, the current World Health Organization classification 
categorizes RMS into three main subtypes: embryonal (encompassing botryoid, spindle cell, and 
anaplastic variants), alveolar (including the solid variant), and pleomorphic.
As with other soft tissue tumors (Almeida et al., 2008), outcome of RMS can be predicted 
according to prognostic factors. Based on such established factors (anatomic site, tumor-node-
metastasis status, and extent of disease after surgical resection), patients are divided into low-, 
intermediate-, and high-risk groups (Dasgupta and Rodeberg, 2012; Parham et al., 2013).
These categories are associated with distinct clinical outcomes. Active research over the 
past two decades has changed the prognosis of RMS. At present, more than 90% of patients in 
the low-risk group will be cured, however, overall survival (OS) is low for patients with high-risk 
RMS, and has not improved (Meza et al., 2006; Dasgupta and Rodeberg, 2012). Prognosis is 
linked not only to disease stage, but also to the aggressiveness of individual malignancies, which 
is characterized by high potential for metastasis and resistance to antitumor therapy (Meza et al., 
2006). To identify factors that contribute to poor RMS prognosis, researchers have studied many 
potentially associated molecular markers.
Nestin, a class VI intermediate filament protein, is expressed in a number of cell types, 
including neural crest and skeletal muscle progenitor cells (Lendahl et al., 1990; Pallari et al., 2011). 
Initially regarded as a marker of neural stem cells, it has subsequently been established that nestin 
is abundantly expressed in embryonic stem cells. In adults, nestin is only found in tissues under 
reactive conditions, such as those during glial scar formation following injury to the central nervous 
system, and during regeneration of injured skeletal muscle tissue (Wiese et al., 2004). Although 
the precise function of nestin remains to be elucidated, studies suggest that it may play a role in 
the control of cell proliferation, survival, and differentiation. This protein is also a putative marker 
of cancer stem cells (Yang et al., 2008), and recent studies have demonstrated that nestin levels 
in tumor cells correlate with the malignant grade and undifferentiated state of cancers including 
glioma, melanoma, RMS, gastrointestinal and testicular stromal tumors, and adrenocortical tumors 
(Yang et al., 2008; Krupkova et al., 2010).
Owing to its expression in many types of human solid tumors, nestin may also serve as 
a diagnostic and possibly prognostic marker of tumor malignancy. Detailed analyses of nestin 
expression patterns in various tumor tissues including RMS would be helpful to establish its role 
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in mechanisms of tumor growth and invasion, and identify novel therapeutic targets. In this study, 
we investigated the expression of nestin in RMS cells by immunohistochemistry, and assessed its 
possible correlation with tumor prognosis.
MATERIAL AND METHODS
Patients
This study included 30 patients treated for RMS between 1995 and 2012. Records from 
the Soft Tissue and Bone Registry of the Institute of Pathology, Medical School, University of 
Belgrade, Serbia, were reviewed for all patients.
Histopathological diagnosis was made according to International Classification of 
Rhabdomyosarcoma criteria, in accordance with the Intergroup Rhabdomyosarcoma Study (IRS) 
Group (Newton et al., 1995). The following primary antibodies were used to confirm diagnoses: 
anti-desmin, anti-vimentin, anti-myogenin, AE1/AE3, and anti-INI-1. Histologically, tumors were 
divided into embryonal, alveolar, and pleomorphic subtypes. All 30 cases were reviewed and 
histological types confirmed by two of the authors (J.S. and S.G.).
Patient characteristics are summarized in Table 1. The majority of patients were men 
(63.3%), with an average age of 29.14 ± 25.84 years (range = 0.8-77.0 years, median = 18.5 years) 
and most showed disseminated disease (60.0%). The upper extremity was the most frequently 
observed disease site (46.4%), and tumors >5 cm were observed in 70.0% of patients. The most 
common histological subtype was embryonal (40.0%). Low- and high-grade RMS were equally 
represented, and the follow-up period was 5 years (range = 10-60 months). OS time was defined 
as the time between the date of diagnosis and the date of death. Patients still alive at the final 
follow-up date were censored.
Characteristic Value
All patients, N 30
Gender, N (%)
   Male 19 (63.3)
   Female  11 (36.7)
Age, years (median; range) 29.14 ± 25.84 (18.5; 0.8-77)
Primary site, N (%)
   Upper extremity 14 (46,7)
   Lower extremity 12 (40.0)
   Trunk   4 (13.3)
Histological type, N (%)
   Embryonal 12 (40.0)
   Alveolar  10 (33.3)
   Pleomorphic   8 (26.7)
Metastasis N (%) 
   Yes 18 (60.0)
   No 12 (40.0)
Tumor size, N (%) 
   ≤5 cm   9 (30.0)
   >5 cm 21 (70.0)
Grade, N (%) 
   Low 15 (50.0)
   High 15 (50.0)
Vital status, N (%) 
   Alive 19 (63.3)
   Dead 11 (36.7)
Table 1. Clinical characteristics of the patients.
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Immunohistochemical procedure
Immunohistochemical analysis of nestin was performed on 5-μm tissue sections 
prepared from paraffin blocks. Sections (5-μm thick) from formalin-fixed, paraffin-embedded 
tissue samples were deparaffinized and treated with 3% hydrogen peroxide for 15 min to block 
endogenous peroxidase activity. Heat-induced antigen retrieval was carried out by immersing 
tissue sections in 0.01 M citrate buffer, pH 6.0, and heating them in a microwave oven for 20 min 
at 620 W. After cooling off for 30 min at room temperature, blocking peptide (Dako, Glostrup, 
Denmark) was utilized to block non-specific staining. Tissue sections were then incubated 
overnight at 4°C with anti-nestin rabbit monoclonal primary antibody (clone SP103, 1:100 dilution; 
Abcam Inc., Cambridge, MA, USA). Using an LSAB+ kit (Dako), the streptavidin-biotin technique 
was applied, with diaminobenzidine as the chromogen solution and Mayer’s hematoxylin as the 
counterstain. Human kidney tissue was included in every staining procedure as a positive control 
for nestin, while incubation with pure antibody diluent (without the primary antibody) served as 
a negative control.
Cytoplasmic expression of nestin was then determined. All immunostained sections were 
independently evaluated by two authors (J.S. and S.G.). Immunohistochemical staining results 
were scored using a semiquantitative technique according to the following categories: absence 
of staining in all tumor cells (negative staining; -); positive staining in less than 10% of cells (focal 
expression; +); 10-50% positive cells (moderate expression; ++); and more than 50% positive cells 
(diffuse expression; +++). For statistical analyses, cases showing negative or focal expression were 
grouped together, as were those with moderate or diffuse expression. These latter two categories 
were regarded as having >50% nestin-positive tumor cells, and the former ≤50%. Immunostaining 
intensity was also evaluated in endothelial cells, as an internal positive control.
Statistical analysis
Statistical analyses were performed with SPSS 18.0 for Windows (SPSS Inc., Chicago, 
IL, USA). At the beginning of the study, all variables were described using the classical methods 
of descriptive statistics (absolute and relative numbers). In order to test differences between 
parameters, the Pearson chi-square chi-square test was used. For each clinical and morphological 
variable, associations with  vital  status and overall survivalsurvival and OS were assessed by 
univariate analysis using the Kaplan-Meier method and log-rank test. Univariate and multivariate 
regression analyses were performed using the Cox proportional hazards regression model to 
analyze independent factors related to prognosis. P values < 0.05 were considered significant.
RESULTS
The analysis of OS for all patients (N = 30) revealed that 93.3, 83.3, 66.7, and 63.3% of 
patients were alive after 1, 2, 3, and 4 years, respectively, and this proportion did not change during 
the fifth year of follow-up (Figure 1). Statistically significant correlation was found for survival and 
histological types of RMS (P = 0.004), tumor grade (P = 0.001) and nestin expression (P = 0.044) 
(Table 2). The highest survival rate was observed in the group of patients with embryonal type of 
RMS, in which none of whom died during the follow-up period (Figure 1). In the group of subjects 
with low-grade tumors, none of the patients died in the first two years of follow-up (Figure 1).
14653Nestin expression in rhabdomyosarcoma
©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research X (X): XXX-XXX (2015)
The highest survival rate was observed in patients with embryonal RMS, none of whom 
died during the follow-up period (P = 0.004). Survival of patients with alveolar RMS was 90% after 
1 year, 80% after 2 years, 40% after 3, and 30% after 4, as it was after 5 years. Pleomorphic RMS 
patients showed survival rates of 87.5, 62.5, and 50% after 1, 2, and 3 years, respectively, and this 
proportion had not changed by the end of the follow-up period (Figure 1).
We found no significant association between other examined parameters and survival.
Figure 1. (a) Overall survival rate for all patients. Survival rate according to (b) histological subtype, (c) tumor grade, 
and (d) nestin protein expression.
Observed characteristics   Overall survival (%)   P value
 1-year 2-year 3-year 4-year 5-year
Histological type
   Embryonal 100.0 100.0 100.0 100.0 100.0 0.004*
   Alveolar   90.0   80.0   40.0   30.0   30.0 
   Pleomorphic    87.5   62.5   50.0   50.0   50.0 
Grade
   Low  100.0 100.0   93.3   93.3   93.3 0.001*
   High   86.7   66.7   40.0   33.3   33.3 
Nestin
   ≤50% positive cells    90.0   70.0   40.0   40.0   40.0 0.044*
   >50% positive cells   95.0   90.0   80.0   75.0   75.0
Table 2. Survival in relation to pathohistology and nestin protein expression.
*Statistically significant, log-rank test.
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Histological tumor grade had a statistically significant effect on survival (P = 0.001; Table 
3). None of the subjects with low-grade tumors died during the first 2 years of follow-up (Figure 1). 
After 3 years, survival among this group of patients was 93.3%, and remained at this level until the 
end of the observation period. In the high-grade tumor group, the survival rate was 86.7, 66.7, 40, 
33.3, and 33.3% after 1, 2, 3, 4, and 5 years, respectively (Figure 1).
Characteristic                                         Univariate                                            Multivariate
 Exp(B)# (95%CI) P value Exp(B) (95%CI) P value
Gender 0.607 (0.161-2.290)  - 
Age 1.039 (1.014-1.063) 0.002* 1.021 (0.987-1.056) 0.231
Primary site 0.907 (0.395-2.080) 0.817 - -
Histological type 2.632 (1.214-5.706) 0.014* 1.573 (0.477-5.188) 0.457
Metastasis 1.410 (0.430-4.623) 0.571 - -
Tumor size   2.349 (0.507-10.886) 0.926 - -
Grade   14.656 (1.865-115.148) 0.011*   4.013 (0.219-73.536) 0.349
Nestin expression 0.314 (0.095-1.038) 0.058 - -
Table 3. Univariate and multivariate Cox regression analysis of the impact of observed factors on survival.
*Statistically significant; #relative risk. CI = confidence interval.
We observed that survival was significantly influenced by nestin protein expression (P = 0.044; 
Table 2). Higher rates of survival were seen in the group with >50% nestin-positive cells (Figures 1 and 
2), with 95, 90, 80, 75, and 75% of such patients being alive after 1, 2, 3, 4, and 5 years, respectively. 
Survival of patients with ≤50% nestin-positive cells was 90% after 1 year, 70% after 2 years, and 40% 
after 3, at which level this figure remained until the end of the investigation period.
Figure 2. Immunohistochemical staining at 400X magnification. Nestin expression in ≤50% of tumor cells in (a) 
pleomorphic RMS, and >50% of tumor cells in (b) embryonal RMS, and (c) and (d) alveolar RMS.
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Cox’s univariate regression analysis showed that age, histological type, and grade 
significantly affected survival, while nestin expression demonstrated borderline significance (P 
= 0.058). However, multivariate Cox regression analysis did not identify any of these factors as 
predictors of survival (Table 3).
Table 4 shows the correlation of nestin expression and clinicopathological variables of 
the examined patients. The analysis showed statistical significance regarding the age of patients 
(P = 0.028) and the tumor grade (P = 0.022). The nestin expression in >50% of tumor cells was 
associated with younger age and also with low grade RMS. There was no statistical association 
between the nestin expression and other parameters.
Characteristic                                                                    Nestin expression  P value
 ≤50% positive cells >50% positive cells
Gender, N (%)   
   Male     8 (42.1)    11 (57.9) 0.246a
   Female     2 (18.2)      9 (81.8) 
Age, years 43.60 ± 27.58 21.92 ± 22.23 0.028b*
Primary site, N (%)   
   Upper extremity    5 (35.7)      9 (64.3) 0.923c
   Lower extremity    4 (33.3)      8 (66.7) 
   Trunk 1 (25)   3 (75) 
Histological type, N (%)   
   Embryonal    2 (16.7)    10 (83.3) 0.100c
   Alveolar 3 (30)   7 (70) 0.406d
   Pleomorphic    5 (62.5)      3 (37.5) 0.062e
   0.342f
Metastatic disease, N (%)   
   Yes    6 (33.3)    12 (66.7) 1.000a
   No    4 (33.3)      8 (66.7) 
Tumor size, N (%)   
   ≤5 cm    3 (33.3)      6 (66.7) 1.000a
   >5 cm    7 (33.3)    14 (66.7) 
Grade, N (%)   
   Low 3 (20) 12 (80) 0.0220a*
   High    7 (46.7)      8 (53.3) 
Vital status   
   Alive 4 (21) 15 (79) 0.108a
   Dead    6 (54.5)      5 (45.5)
*Statistically significant; aFisher test; bt-test; cchi-square test; dembryonal vs alveolar; eembryonal vs pleomorphic; 
falveolar vs pleomorphic.
Table 4. Correlation between nestin expression and clinical and morphological characteristics.
DISCUSSION
Soft tissue sarcomas account for less than 1% of all adult malignancies. Although 
infrequent in adults, RMS is a common childhood cancer, representing more than 50% of all soft 
tissue pediatric sarcomas (Ferrari et al., 2003; Sultan et al., 2009). Due to the rarity of adult RMS, 
information regarding its clinical and biological characteristics is very limited. Multiple adverse 
clinical factors appear to converge in patients with RMS, yet little is known about this disease.
Here, we studied a group of 30 patients with pathohistological diagnoses of RMS. We 
noticed that men were slightly overrepresented and that tumors >5 cm were frequently observed 
(70%). Nevertheless, primary tumor size >5 cm did not significantly affect patient outcome. Upper 
extremities were the most common primary tumor sites, followed by the lower extremities and 
trunk, but this factor did not considerably affect OS.
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This study included adult and juvenile patients, the youngest being less than 1 year old and 
the oldest 77 years old. After the median follow-up period of 3.9 years, 63.3% were reported to be 
alive. As many other researchers have reported, better outcome was observed in the younger patient 
group (<18 years old), only one of whom died during the 5 years of follow-up. In contrast, of the older 
patients (>18 years old), 10/15 died in the same period (Hosoi et al., 2007; Sultan et al., 2009; Badr 
et al., 2012). The most likely reason for this is the fact that among younger patients, embryonal RMS 
was the most common diagnosis (80%), while this histological type was not found in the older patient 
group (0.001). Adult RMS patients show a high incidence of pleomorphic and alveolar malignancies. 
Indeed, RMS histological type significantly differed with patient age (P < 0.001; La Quaglia et al., 
1994; Furlong and Fanburg-Smith, 2001; Allen et al., 2007; Stock et al., 2009).
In our study group, the most frequent histological type was embryonal, followed by 
alveolar, and pleomorphic (40, 33.3 and 26,7% respectively). The highest survival rate was seen in 
patients with the embryonal subtype, none of whom died during the follow-up period. A comparison 
of the histologic subtypes included revealed this difference to be statistically significant (Little et al., 
2002; Dumont et al., 2013). There is conflicting evidence concerning the prognostic significance of 
histologic subtype (Crist et al., 1990; Crist et al., 2001; Hawkins et al., 2001). Although histology 
was found to be an important prognostic variable in the second IRS (Dumont et al., 2013), it was 
not included as an independent prognostic factor in IRS-IV (Crist et al., 1990; Crist et al., 2001).
Other lines of evidence suggest that histologic subtype may constitute an independent 
contributor to prognosis. An evaluation of 159 RMS patients treated at the National Cancer Institute 
over a 15-year period revealed a better outcome for embryonal RMS than identically treated 
alveolar or pleomorphic variants (Dagher and Helman, 1999; Raney et al., 2001; Company et al., 
2011; Dumont et al., 2013). The results of our study are consistent with recent publications. As 
many other authors have reported, we have shown that both histologic subtype and tumor grade 
significantly correlate with patient prognosis (Tsokos et al., 1992; Ferrari et al., 2003; Company et 
al., 2011). The 5-year survival rate of patients suffering high-grade RMS was 33.3%, significantly 
lower than that of those with low-grade RMS (93.3%; P = 0.001; Furlong et al., 2001; Raney et al., 
2010; Dumont et al., 2013).
The intermediate filament protein nestin, a well-known marker of neural progenitor cells, 
has been detected in a multitude of cellular phenotypes in embryonic and adult tissues. Although 
nestin is typically found in neural stem cells, it has also been observed in other cell and tissue 
types during mammalian embryogenesis, e.g. cardiac and skeletal muscles, umbilical cord blood, 
Sertoli and interstitial testicular cells, odontoblasts, hair follicle sheath cells, hepatic cells, and renal 
progenitors (Wiese et al., 2004; Krupkova et al., 2010).
In adults, nestin expression is not limited to the nervous system, appearing in healthy 
tissue, as well as during injuries or other pathological events. In general, the presence of nestin in 
the cells of adults indicates an undifferentiated state, plasticity, increased mobility, or pathological 
conditions (Krupkova et al., 2010). To date, numerous studies have shown that some cancer cells 
share many similar features with mammalian cells during embryogenesis. One such characteristic 
is the expression pattern of intermediate filament proteins such as nestin (Veselska et al., 2012). 
Nestin expression has been demonstrated in many types of malignancies of various origins 
(Krupkova et al., 2010). Furthermore, the occurrence of nestin-positive tumor cells has been 
associated with dedifferentiation and advanced grade in some cancers (Strojnik et al., 2007; Yang 
et al., 2008; Ishiwata et al., 2011; Wan et al., 2011; Skarda et al., 2012).
On the other hand, some clinical studies have demonstrated that nestin expression does not 
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seem to be a powerful prognostic factor (Chinnaiyan et al., 2008; Kim et al., 2011; Lenz et al., 2011; 
Zambo et al., 2012). Many questions remain concerning the functional role and regulation of nestin 
expression in undifferentiated tissues, and the mechanisms relating to this in various solid tumors.
Our results showed that nestin expression significantly correlated with survival (P = 0.044). 
Specifically, a higher survival rate was observed in the group of cases showing nestin expression 
in > 50% of cells. When we analyzed nestin expression in relation to histological type, the majority 
of embryonal and alveolar RMS cases (83.3 and 70.0%, respectively) demonstrated expression 
in more than 50% of tumor cells, while the majority of pleomorphic RMS cases (62.5%) showed 
negative or focal expression. In addition, the extent of nestin expression was lower in high-grade 
than in low-grade RMS. Consistent with these results, we have shown that older RMS patients 
exhibited negative expression more often than younger patients, and this result was statistically 
significant (P = 0.028). Our findings might be explained by the fact that we did not analyze 
morphological subtypes of RMS, owing to the small number of patients included. RMS comprises 
a group of morphologically similar but biologically diverse lesions. For example, embryonal RMS 
was the most common type in our study, but its pattern of development is highly variable, ranging 
from poorly to well-differentiated tumors (Furlong and Fanburg-Smith, 2001; Parham et al., 2013).
Of the few studies to date that have analyzed nestin expression in RMS, all have reported 
strong expression in the majority of embryonal and alveolar cases (Kobayashi et al., 1998; Shimada 
et al., 2007; Sadikovic et al., 2011; Sana et al., 2011). However, none have investigated nestin 
expression in pleomorphic RMS. In addition, these studies did not examine the correlation between 
nestin expression and established prognostic factors (such as primary site, tumor size, distant 
metastases, age at diagnosis, and histology), nor its association with survival.
CONCLUSION
Nestin overexpression was observed in most embryonal RMS cases, low-grade tumors, 
in early stages of the disease, and among younger sufferers. Our results lead us to propose nestin 
expression as a possible positive prognostic factor in RMS.
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